{"prompt": "['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 39 of 128', '6 Trial objectives and endpoints', 'Panel 3: Objectives and endpoints', 'Objectives', 'Endpoints', 'Primary objective', 'Primary and secondary endpoints', 'To establish the dose-response', 'Primary endpoint', 'relationship of twice daily', \"Investigator's Global Assessment (IGA) score of 0 (clear) or\", 'applications of delgocitinib', '1 (almost clear) with at least a 2-step improvement', 'cream 1, 3, 8, and 20 mg/g and', '(IGA TS) from baseline to Week 16.', 'delgocitinib cream vehicle for', '16 weeks in the treatment of', 'Secondary endpoints', 'subjects with mild to severe', 'Change in Hand Eczema Severity Index (HECSI) from', 'chronic hand eczema.', 'baseline to Week 16.', 'Time to IGA TS.', 'Other objectives', 'Other endpoints', 'To compare the safety of twice', 'Safety and tolerability', 'daily applications of', 'Number of adverse events (AEs).', 'delgocitinib cream 1, 3, 8, and', '20 mg/g with delgocitinib', 'cream vehicle for 16 weeks in', 'the treatment of subjects with', 'mild to severe chronic hand', 'eczema.', 'To evaluate the health-related', 'Health-related quality of life and efficacy', 'quality of life and efficacy of', 'Change in Chronic Hand Eczema Symptom Diary (HESD)', 'twice daily applications of', '(weekly average for each individual symptom) from', 'delgocitinib cream 1, 3, 8, and', 'baseline to Week 16.', '20 mg/g compared to', 'Reduction in worst pruritus (\"itch\" - one of the', 'delgocitinib cream vehicle for', 'symptoms captured in HESD) (weekly average) of', '16 weeks in the treatment of', '>4 points from baseline to Week 16 among subjects with', 'subjects with mild to severe', 'baseline worst pruritus (weekly average) >4.', 'chronic hand eczema.', 'Change in Chronic Hand Eczema Impact Scale (HEIS) from', 'baseline to Week 16.', \"Patient's Global Assessment (PaGA) TS at Week 16.\", 'PaGA TS refers to achieving:', 'PaGA score of 0 (clear) when classified at baseline as', '1 (almost clear) or 2 (mild),', 'or', 'PaGA score of 0 (clear) or 1 (almost clear) when classified', 'at baseline as 3 (moderate) or 4 (severe).', 'Time to PaGA TS.']['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 40 of 128', 'Objectives', 'Endpoints', 'Reduction in Dermatology Life Quality Index (DLQI) of', '>4 points from baseline to Week 16 among subjects with', 'baseline DLQI>4.', 'Change in DLQI score from baseline to Week 16.', 'Change in EuroQoL 5-dimension 5-level questionnaire (EQ-', '5D-5L) from baseline to Week 16.', 'Change in Quality of Life in Hand Eczema Questionnaire', '(QOLHEQ) from baseline to Week 16.', 'Change in Work Limitation Questionnaire (WLQ) from', 'baseline to Week 16.', 'Efficacy over time', 'IGA TS at each scheduled assessment until and including', 'Week 14.', 'PaGA TS at each scheduled assessment until and including', 'Week 14.', 'Change from baseline to each week from Week 1 to', 'Week 15 in HESD (weekly average for each individual', 'symptom).', 'Reduction of worst pruritus (weekly average) of', '>4 points from baseline to each week from Week 1 to', 'Week 15 among subjects with baseline worst pruritus', '(weekly average) >4.', 'Change from baseline to each scheduled assessment until', 'Week 14 in HEIS.', 'Change in DLQI score from baseline to each scheduled', 'assessment until Week 14.', 'Reduction of DLQI of at least 4 points from baseline to each', 'scheduled assessment until Week 14.', 'To evaluate the effect of', 'Biomarkers', 'delgocitinib on Staphylococcus', 'Change in Staphylococcus aureus colonisation from', 'aureus colonisation of the', 'baseline to Week 16.', 'skin, skin microbiome, skin', 'Change in microbiome composition from baseline to', 'barrier function, and skin', 'Week 16.', 'inflammation.', 'Change in skin barrier function, measured as transepidermal', 'water loss, capacitance, skin pH, and content of natural', 'moisturising factors, from baseline to Week 16.', 'Change in expression of skin barrier proteins and in extent', 'of immune cells in skin biopsies from baseline to Week 16.']\n\n###\n\n", "completion": "END"}